BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 209 filers reported holding BRIDGEBIO PHARMA INC in Q2 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,663,195 | +2728.5% | 745,666 | +1744.9% | 0.01% | – |
| Q2 2023 | $695,172 | +25.3% | 40,417 | +20.8% | 0.00% | – |
| Q1 2023 | $554,949 | +120.7% | 33,471 | +1.4% | 0.00% | – |
| Q4 2022 | $251,438 | -17.6% | 32,997 | +7.8% | 0.00% | – |
| Q3 2022 | $305,000 | +17.3% | 30,619 | +6.6% | 0.00% | – |
| Q2 2022 | $260,000 | -22.6% | 28,712 | -13.2% | 0.00% | – |
| Q1 2022 | $336,000 | -39.6% | 33,083 | -0.8% | 0.00% | – |
| Q4 2021 | $556,000 | -75.4% | 33,358 | -30.8% | 0.00% | -100.0% |
| Q3 2021 | $2,258,000 | -26.6% | 48,174 | -4.5% | 0.00% | -50.0% |
| Q2 2021 | $3,077,000 | +5.1% | 50,468 | +6.1% | 0.00% | 0.0% |
| Q1 2021 | $2,929,000 | -5.7% | 47,546 | +8.8% | 0.00% | 0.0% |
| Q4 2020 | $3,106,000 | +124.9% | 43,687 | +18.7% | 0.00% | +100.0% |
| Q3 2020 | $1,381,000 | +9.3% | 36,808 | -5.0% | 0.00% | 0.0% |
| Q2 2020 | $1,264,000 | +378.8% | 38,764 | +325.8% | 0.00% | – |
| Q1 2020 | $264,000 | – | 9,104 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 3,835,722 | $103,449,000 | 44.18% |
| Kohlberg Kravis Roberts & Co. L.P. | 36,900,661 | $995,211,000 | 12.26% |
| SC US (TTGP), LTD. | 2,544,738 | $68,632,000 | 4.69% |
| Cormorant Asset Management, LP | 2,780,885 | $75,000,000 | 4.31% |
| Perceptive Advisors | 6,706,268 | $180,868,000 | 4.15% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $717,968,000 | 3.22% |
| Hillhouse Capital Management | 2,035,790 | $54,905,000 | 1.75% |
| Alpine Group USVI, LLC | 20,000 | $539,000 | 1.70% |
| HHLR ADVISORS, LTD. | 2,352,900 | $63,458,000 | 1.42% |
| SCGE MANAGEMENT, L.P. | 588,235 | $15,865,000 | 0.79% |